Long Non-coding RNA KTN1-AS1 Targets miR-505 to Promote Glioblastoma Progression

Guo, Kai; Fang, Lingling; Li, Mingjian; Li, Aizheng; Liu, Na

doi:https://doi.org/10.1155/2023/4190849

Behavioural Neurology

On this page

Abstract Introduction Materials and Methods Results Discussion Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2023 | Article ID 4190849 | https://doi.org/10.1155/2023/4190849

Long Non-coding RNA KTN1-AS1 Targets miR-505 to Promote Glioblastoma Progression

Kai Guo,¹Lingling Fang,¹Mingjian Li,¹Aizheng Li,¹and Na Liu²

Academic Editor: Muh-Shi Lin

Received24 Aug 2021

Revised19 Dec 2022

Accepted13 Jan 2023

Published31 Jan 2023

Abstract

Glioblastoma (GBM) is a highly malignant cancer, the prognosis of which is pretty poor. Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs, which play important roles in carcinogenesis process of many cancers including GBM. In this study, we want to clarify the expression, biological function, and molecular mechanism of lncRNA KTN1 antisense RNA 1 (KTN1-AS1) in GBM tumor progression. We found that KTN1-AS1 expression was upregulated in GBM tissues and cell lines. KTN1-AS1 played oncogenic roles to facilitate proliferation, migration, and invasion of GBM cells. Then, we revealed that miR-505 was a target of KTN1-AS1, and its expression was decreased in GBM. KTN1-AS1 contributed to GBM progression by mediating miR-505. Finally, we demonstrated that KTN1-AS1 upregulated some target oncogenes of miR-505 including ZEB2, HMGB1, and RUNX2 in GBM cells. All in all, we concluded that the highly expressed KTN1-AS1 in GBM played oncogenic roles to facilitate GBM progression by targeting miR-505.

1. Introduction

Glioma is the most common primary tumor of the central nervous system, and glioblastoma (GBM) is the most malignant subtype of glioma, which is characterized by an unacceptably high invasive potential [1, 2]. Despite advanced therapies such as surgery, chemotherapy, and radiotherapy have been widely applied in the clinical treatment at present, the prognosis of GBM patients remains poor due to the high malignancy [3, 4]. Therefore, it is vital to study the mechanisms underlying the invasive phenotype of GBM and identify novel therapeutic targets to improve prognosis.

Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs with more than 200 nucleotides [5]. More and more studies indicate that lncRNAs affect a variety of biological processes and play important roles in carcinogenesis process of many cancers including GBM [6, 7]. LncRNAs are able to play biological roles via multiple mechanisms, and the most common one is the competitive endogenous RNAs (ceRNAs) way. In this way, lncRNAs increase the expression of microRNAs (miRNAs) target genes by competitively sponging these miRNAs [8, 9].

LncRNA KTN1 antisense RNA 1 (KTN1-AS1) is a newly identified lncRNA, which has already been reported as an oncogenic gene in several malignant tumors [10–12]. However, to our knowledge, the expression, biological function, and molecular mechanism of KTN1-AS1 in GBM remain still unknown. Therefore, in this study, we want to focus on KTN1-AS1 to clarify its roles in GBM tumor progression.

2. Materials and Methods

2.1. Tissue Samples

Paired GBM tissues and normal paratumor tissues were collected from 40 patients diagnosed with GBM in Weifang People’s Hospital. None of these patients received local or systemic treatment before surgery. This study was approved by the Ethics Committee of Weifang People’s Hospital. All participants enrolled in this study had signed written informed consent.

2.2. Cell Culture and Transfection

Human GBM cell lines (A172, U87, U251, and LN229) and normal human astrocytes (NHA) were obtained from American Type Culture Collection (ATCC, USA). All these cell lines were cultured in dulbecco’s modified eagle medium (DMEM) medium (Gibco, USA) containing 10% fetal bovine serum (FBS) at 37°C with 5% CO₂. Plasmids, siRNAs, miR-505 mimics, miR-505 inhibitors, or corresponding negative controls (NC) were transfected into cells using Lipofectamine 3000 (Invitrogen, USA).

2.3. RT-qPCR

Total RNAs were extracted using TRIzol Reagent (Invitrogen) and reversely transcribed into cDNAs using QuantiTect Reverse Transcription Kit (Qiagen, Germany). Real-time reverse transcription polymerase chain reaction (qRT-PCR) reaction was conducted using SYBR Green qPCR mix kit (Takara, Japan). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and U6 were selected as internal references for quantifying relative expression of lncRNAs and miRNAs, respectively. The relative gene expression was calculated with the 2^−ΔΔCt method. Primer sequences for KTN1-AS1 were, forward: 5′-AGGGAAATTTGGGCAGAAGT-3′ and reverse: 5′-GTTACCCGTGTGAGCCTGAT-3′.

2.4. Western Blot Assay

Total proteins were extracted using Radio Immunoprecipitation Assay (RIPA) buffer (Beyotime, China) containing protease inhibitor and qualified by a BCA Protein Assay Kit (Thermo Scientific, USA). Proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). The membranes were then reacted with specific primary antibodies against ZEB2, HMGB1, RUNX2 (ab138222, ab18256, ab76956, Abcam, USA), and GAPDH (ab8245, Abcam) at 4°C overnight and a secondary antibody at room temperature for 2 hours. Band exposure was performed in the enhanced chemiluminescence (ECL) detection system (Pierce, USA).

2.5. CCK-8 Assay

Cells were seeded in a 96-well plate ( cells/well) 24 hours before transfection. At 24, 48, or 72 hours after transfection, 10 μL Cell Counting Kit-8 (CCK-8) solution was added into each well, and absorbance at 450 nm of each well was recorded after incubating for 1 hour at 37°C.

2.6. 5-Ethynyl-2′-Deoxyuridine (EdU) Assay

Cells were seeded in a 24-well plate ( cells/well) 24 hours before transfection. At 48 hours after transfection, Cell-light EdU Apollo 567 In Vitro Imaging Kit (Ribobio, China) was used to perform EdU assay according to the manufacturer’s instructions.

2.7. Wound-Healing Assay

Cells were seeded in a 24-well plate ( cells/well) and cultured until 90% integration. Confluent monolayers were scratched by using a pipette tip. Images were captured at 0 and 24 hours after culturing with serum-free medium.

2.8. Transwell Assay

Transwell assay was conducted using Matrigel coated chamber (Corning, USA). Cells were transfected for 48 hours and harvested to seed into the upper chamber with serum-free medium. Medium containing 10% FBS was added into the lower chamber. After 24 hours, cells invaded through the membrane were fixed with methanol and stained with 0.1% crystal violet to count cell numbers.

2.9. Luciferase Reporter Assay

KTN1-AS1 sequences containing wild-type (wt) and mutant-type (mut) miR-505 binding sites were inserted into a pGL4 vector to construct KTN1-AS1-wt and KTN1-AS1-mut plasmids. Cells were co-transfected with KTN1-AS1-wt or KTN1-AS1-mut plasmids and miR-505 mimic. Luciferase activity was analyzed using the dual-luciferase reporter assay system (Promega, USA).

2.10. Statistical Analysis

All experiments were carried out at least three times, and data were presented as mean ± SD. The differences between groups were assessed by one-way Analysis of Variance (ANOVA) or Student’s t test using GraphPad Prism Software (V5.0, GraphPad Software, USA). values less than 0.05 were considered statistically significant.

3. Results

3.1. KTN1-AS1 Expression Is Upregulated in GBM Tissues and Cell Lines

In order to explore the expression profile of KTN1-AS1 in GBM, qRT-PCR was applied to measure KTN1-AS1 expression in GBM tissues and cell lines. The result showed that KTN1-AS1 expression was higher in GBM tissues compared with adjacent normal tissues (Figure 1(a)). Moreover, the expression of KTN1-AS1 in GBM cell lines (A172, U87, U251, and LN229) was also higher than that of in NHA cells (Figure 1(b)). All these results indicated an increased KTN1-AS1 expression in GBM tissues and cell lines.

(a)

(b)

3.2. KTN1-AS1 Facilitates Proliferation, Migration, and Invasion in GBM Cells

To investigate the biological functions of KTN1-AS1 in GBM cells, first, KTN1-AS1 was upregulated in A172 cells by transfecting KTN1-AS1 overexpression plasmids and silenced in U251 cells by transfecting KTN1-AS1 siRNAs (Figures 2(a) and 2(b)). Then, CCK-8 assay and EdU assay found that overexpressing KTN1-AS1 significantly enhanced the proliferative ability of A172 cells, and silencing KTN1-AS1 obviously inhibited the proliferation of U251 cells (Figures 2(c), 2(d), 2(e), and 2(f)). Accordingly, wound-healing assay and transwell assay displayed that overexpressing KTN1-AS1 significantly promoted the migration and invasion of A172 cells, and silencing KTN1-AS1 suppressed the migration and invasion of U251 cells (Figures 2(g), 2(h), 2(i), and 2(j)). These results implied that KTN1-AS1 played oncogenic roles to facilitate malignant processes of GBM cells.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

3.3. MiR-505 Is a Target of KTN1-AS1

To investigate the regulatory mechanism of KTN1-AS1, we used StarBase database to find the target miRNAs of KTN1-AS1. MiR-505, which had been reported to function as a tumor suppressor gene, was chosen for validation. The predicted binding site (Figure 3(a)) was subsequently verified by luciferase reporter assay (Figure 3(b)). We also demonstrated that miR-505 was significantly downregulated in GBM tissues and cell lines (Figures 3(c) and 3(d)). These data showed that miR-505 was a target of KTN1-AS1, and its expression was decreased in GBM.

(a)

(b)

(c)

(d)

3.4. KTN1-AS1 Contributes to GBM Progression by Mediating miR-505

Then, we further determined the roles of miR-505 in KTN1-AS1 induced GBM progression. Our data showed that overexpression of miR-505 significantly reversed the KTN1-AS1 caused proliferation, migration, and invasion acceleration in A172 cells (Figures 4(a), 4(b), 4(c), and 4(d)). Similarly, inhibition of miR-505 rescued the proliferation, migration, and invasion suppression induced by KTN1-AS1 silence in U251 cells (Figures 4(e), 4(f), 4(g), and 4(h)). The above data suggested that KTN1-AS1 contributed to GBM progression by mediating miR-505.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

3.5. KTN1-AS1 Upregulates Target Oncogenes of miR-505

Finally, we studied the regulation of KTN1-AS1 on some target genes of miR-505 including ZEB2, HMGB1, and RUNX2 in GBM cells. Our data showed that the expression of these oncogenes was significantly raised by KTN1-AS1, which could be attenuated by miR-505 in A172 cells (Figure 5(a)). Accordingly, the expression of these oncogenes significantly decreased after KTN1-AS1 silencing, which could be reversed by miR-505 inhibition in U251 cells (Figure 5(b)). The above data suggested that KTN1-AS1 upregulated these target oncogenes of miR-505 by mediating miR-505.

(a)

(b)

4. Discussion

GBM is generally considered as a very infiltrative and malignant brain tumor, and its pathogenesis involves the dysregulation of many oncogenes and tumor suppressor genes [13]. More and more evidences have proved that lncRNAs participate in the pathogenesis of many cancers, including GBM [14, 15]. Although many research has been conducted to uncover the potential roles of lncRNAs in GBM progression, while only limited lncRNAs have been reported, and the functions of most lncRNAs remain unclear in GBM. KTN1-AS1 is a novel lncRNA, which has been reported to be upregulated and exert carcinogenesis in some other cancers but not in GBM [10–12]. Hence, in our present research, the expression, biological function, and molecular mechanism of KTN1-AS1 in GBM were investigated.

First, we showed that KTN1-AS1 expression was higher in GBM tissues than that of in adjacent normal tissues and was higher in GBM cell lines than that of in NHA cells. We concluded that KTN1-AS1 expression was increased in GBM tissues and cell lines, indicating that it might play oncogenic roles in GBM. Subsequently, we conducted in vitro experiments and found that overexpressing KTN1-AS1 in GBM cells was able to promote proliferation, migration, and invasion, while silencing KTN1-AS1 have the reverse impacts. So we considered that the highly expressed KTN1-AS1 in GBM played oncogenic roles to facilitate malignant processes of GBM cells.

LncRNAs always exert their roles by binding with miRNAs [8, 9]. Herein, we predicted that miR-505 might bind to KTN1-AS1 and then verified it by luciferase reporter assay. We also demonstrated that miR-505 was significantly downregulated in GBM tissues and cell lines. According to many studies, miR-505 has been proved to act as a tumor suppressor gene in some cancers, including pancreatic cancer [16], prostate cancer [17], non-small cell lung cancer [18], hepatocellular carcinoma [19], and so on. In GBM, miR-505 could inactivate the Wnt/β-catenin signaling pathway by directly targeting and inhibiting WNT7B to inhibit tumorigenesis as a tumor suppressor [20]. Then, we further determined that overexpression of miR-505 significantly reversed the effects of KTN1-AS1, and inhibition of miR-505 rescued the influence of KTN1-AS1 silence in GBM cells. So we concluded that KTN1-AS1 contributed to GBM progression by mediating miR-505.

Because lncRNAs could increase the expression of miRNAs target genes in the ceRNA manner, so we explored the downstream genes of KTN1-AS1/miR-505 axis. We displayed that the expression of some validated miR-505 targeted oncogenes genes including ZEB2, HMGB1, and RUNX2 [21–23] was significantly raised by KTN1-AS1 and downregulated by miR-505. ZEB2 is a transcription factor that mainly promotes epithelial-to-mesenchymal transition and regulating differentiation, cancer stem cell-like traits, apoptosis, cell cycle arrest, and metastasis of cancers [24]. Aberrant HMGB1 expression has been reported in different types of cancers, and many studies also verified the promoting role of HMGB1 in the genesis of some cancers including GBM [25, 26]. RUNX2 level has been reported to be upregulated in GBM, and the cross-talk between Cyclic 3′,5′-adenosinemonophosphate/protein kinase A (c-AMP/PKA) signaling and RUNX2 can promote the malignant phenotype of GBM cells [27]. We think that KTN1-AS1 may play oncogenic roles by upregulating these oncogenes by mediating miR-505. Therefore, targeting KTN1-AS1 or overexpression of miR-505 may have potential anti-tumor effect, which are important theoretical basis for clinical implications.

In conclusion, this study presented that lncRNA KTN1-AS1 was upregulated in GBM and played oncogenic roles to facilitate proliferation, migration, and invasion of GBM cells by targeting miR-505. KTN1-AS1 could serve as an underlying therapeutic target for GBM.

Data Availability

Data supporting this research article are available from the corresponding author or first author on reasonable request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was supported by Fund project of Weifang Science and Technology Bureau (Grant no. JB33301).

References

L. Wang, A. Karpova, M. A. Gritsenko et al., “Proteogenomic and metabolomic characterization of human glioblastoma,” Cancer Cell, vol. 39, no. 4, pp. 509–528.e20, 2021.
View at: Google Scholar
A. C. Tan, D. M. Ashley, G. Y. López, M. Malinzak, H. S. Friedman, and M. Khasraw, “Management of glioblastoma: state of the art and future directions,” CA: a Cancer Journal for Clinicians, vol. 70, no. 4, pp. 299–312, 2020.
View at: Publisher Site | Google Scholar
T. I. Janjua, P. Rewatkar, A. Ahmed-Cox et al., “Frontiers in the treatment of glioblastoma: past, present and emerging,” Advanced Drug Delivery Reviews, vol. 171, pp. 108–138, 2021.
View at: Publisher Site | Google Scholar
K. White, K. Connor, J. Clerkin et al., “New hints towards a precision medicine strategy for IDH wild-type glioblastoma,” Annals of Oncology, vol. 31, no. 12, pp. 1679–1692, 2020.
View at: Publisher Site | Google Scholar
T. Ali and P. Grote, “Beyond the RNA-dependent function of LncRNA genes,” eLife, vol. 9, p. 9, 2020.
View at: Publisher Site | Google Scholar
D. Fu, Y. Shi, J. Liu et al., “Targeting long non-coding RNA to therapeutically regulate gene expression in cancer,” Molecular Therapy Nucleic Acids, vol. 21, pp. 712–724, 2020.
View at: Publisher Site | Google Scholar
Z. Peng, C. Liu, and M. Wu, “New insights into long noncoding RNAs and their roles in glioma,” Molecular Cancer, vol. 17, no. 1, p. 61, 2018.
View at: Publisher Site | Google Scholar
Y. Tay, J. Rinn, and P. P. Pandolfi, “The multilayered complexity of ceRNA crosstalk and competition,” Nature, vol. 505, no. 7483, pp. 344–352, 2014.
View at: Publisher Site | Google Scholar
Y. Yu, F. Gao, Q. He, G. Li, and G. Ding, “lncRNA UCA1 functions as a ceRNA to promote prostate cancer progression via sponging miR143,” Molecular Therapy Nucleic Acids, vol. 19, pp. 751–758, 2020.
View at: Publisher Site | Google Scholar
X. Hu, L. Xiang, D. He et al., “The long noncoding RNA KTN1-AS1 promotes bladder cancer tumorigenesis via KTN1 cis-activation and the consequent initiation of Rho GTPase-mediated signaling,” Clinical Science, vol. 135, no. 3, pp. 555–574, 2021.
View at: Publisher Site | Google Scholar
C. Li, W. Zhao, X. Pan et al., “LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1,” Oncogene, vol. 39, no. 39, pp. 6157–6171, 2020.
View at: Publisher Site | Google Scholar
C. Liu, X. Li, Y. Hao et al., “STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis,” Aging, vol. 12, no. 9, pp. 8680–8701, 2020.
View at: Publisher Site | Google Scholar
M. Karsy, J. Guan, A. L. Cohen, R. L. Jensen, and H. Colman, “New molecular considerations for glioma: IDH, ATRX, BRAF, TERT, H3 K27M,” Current Neurology and Neuroscience Reports, vol. 17, no. 2, p. 19, 2017.
View at: Publisher Site | Google Scholar
C. T. Stackhouse, G. Y. Gillespie, and C. D. Willey, “Exploring the roles of lncRNAs in GBM pathophysiology and their therapeutic potential,” Cell, vol. 9, no. 11, p. 2369, 2020.
View at: Google Scholar
R. Paulmurugan, M. Malhotra, and T. F. Massoud, “The protean world of non-coding RNAs in glioblastoma,” Journal of Molecular Medicine, vol. 97, no. 7, pp. 909–925, 2019.
View at: Publisher Site | Google Scholar
Z. Xu, D. Zhang, Z. Zhang et al., “MicroRNA-505, suppressed by oncogenic long non-coding RNA LINC01448, acts as a novel suppressor of glycolysis and tumor progression through inhibiting HK2 expression in pancreatic cancer,” Frontiers in Cell and Development Biology, vol. 8, p. 625056, 2020.
View at: Google Scholar
Y. Zhang, F. Lv, L. Qiao, and Q. Zhao, “MiR-505 inhibits prostate cancer cell invasion, metastasis and epithelial-to-mesenchymal transition through targeting HMGB-1,” Journal of BUON, vol. 25, no. 4, pp. 2036–2044, 2020.
View at: Google Scholar
P. Zhu, Z. Liu, H. Huang, C. Zhong, and Y. Zhou, “MiRNA505/NET1 axis acts as a CD8 T-TIL regulator in non-small cell lung cancer,” Oncotargets and Therapy, vol. 13, pp. 9785–9795, 2020.
View at: Publisher Site | Google Scholar
X. Chi, Y. Jiang, Y. Chen et al., “microR-505/heterogeneous nuclear ribonucleoprotein M inhibits hepatocellular carcinoma cell proliferation and induces cell apoptosis through the Wnt/β-catenin signaling pathway,” Biomarkers in Medicine, vol. 14, no. 11, pp. 981–996, 2020.
View at: Publisher Site | Google Scholar
C. Zhang, X. Yang, C. Fu, and X. Liu, “Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway,” Gene, vol. 672, pp. 172–179, 2018.
View at: Publisher Site | Google Scholar
S. Feng, W. Liu, X. Bai et al., “LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer,” Cancer Letters, vol. 465, pp. 105–117, 2019.
View at: Publisher Site | Google Scholar
L. Li, G. Lv, B. Wang, and H. Ma, “Long noncoding RNA LINC00525 promotes the aggressive phenotype of chordoma through acting as a microRNA-505-3p sponge and consequently raising HMGB1 expression,” Oncotargets and Therapy, vol. 13, pp. 9015–9027, 2020.
View at: Publisher Site | Google Scholar
P. Zhao, H. Guan, Z. Dai, Y. Ma, Y. Zhao, and D. Liu, “Long noncoding RNA DLX6-AS1 promotes breast cancer progression via miR-505-3p/RUNX2 axis,” European Journal of Pharmacology, vol. 865, p. 172778, 2019.
View at: Publisher Site | Google Scholar
M. Fardi, A. Mo, B. Baradaran et al., “The crucial role of ZEB2: from development to epithelial-to-mesenchymal transition and cancer complexity,” Journal of Cellular Physiology, vol. 234, no. 9, pp. 14783–14799, 2019.
View at: Publisher Site | Google Scholar
A. Tripathi, K. Shrinet, and A. Kumar, “HMGB1 protein as a novel target for cancer,” Toxicology Reports, vol. 6, pp. 253–261, 2019.
View at: Publisher Site | Google Scholar
X. Y. Gao, J. Zang, M. H. Zheng et al., “Temozolomide treatment induces HMGB1 to promote the formation of glioma stem cells via the TLR2/NEAT1/Wnt pathway in glioblastoma,” Frontiers in Cell and Development Biology, vol. 9, p. 620883, 2021.
View at: Google Scholar
D. Yamada, K. Fujikawa, K. Kawabe, T. Furuta, M. Nakada, and T. Takarada, “RUNX2 promotes malignant progression in glioma,” Neurochemical Research, vol. 43, no. 11, pp. 2047–2054, 2018.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Kai Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

333

Downloads

376

Citations